Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 2

Clinical Considerations for 2L Treatment Sequencing in mCRC

, , , ,

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

  1. Dr Marshall to Dr Ciombor: What is your current approach for treatment sequencing in the 2L for patients with mCRC that are chemotherapy-refractory?
    • How does prior line of therapy impact your treatment decision-making?